Xeris Biopharma price target raised to $7 from $6 at Oppenheimer

Oppenheimer raised the firm’s price target on Xeris Biopharma (XERS) to $7 from $6 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 total revenue of $60.1M, which topped OpCo/consensus estimates on solid Recorlev/Gvoke performance and Keveyis durability. Management tightened full-year guidance to $260M-$275M from $255M-$275M, and the firm expects adjusted EBITDA to be consistently positive going forward. No apparent tariff threat as manufacturing is wholly domestic. Oppenheimer looks forward to the June 3 analyst day at which a key focus will be the company’s subcutaneous levothyroxine for hypothyroidism.